{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-26-000044","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-08-03T20:06:40+00:00","discovered_at":"2026-08-03T20:08:08.476928+00:00","generated_at":"2026-08-03T20:08:48.385317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jazz Pharma Q2 2026: record revenue $1.2B (+16% YoY); raises FY2026 guidance to $4.60-$4.75B","bullets":["Total revenues of $1.2B, a record, up 16% YoY; GAAP EPS $2.78, non-GAAP adjusted EPS $5.71.","Xywav revenues +13% YoY with 525 net patient adds in Q2; Epidiolex revenues +16% YoY.","Company raises 2026 revenue guidance to $4.60-$4.75B, reflecting double-digit growth from Xywav and epilepsy/oncology.","FDA set PDUFA date of Aug 25, 2026 for zanidatamab sBLA in 1L GEA; BTD granted for HER2+ CRC.","Cash from operations $824M in first half 2026; strong balance sheet supports pipeline and launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-26-000044","json":"https://secwatch.observer/filing/0001232524-26-000044.json","markdown":"https://secwatch.observer/filing/0001232524-26-000044.md","text":"https://secwatch.observer/filing/0001232524-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/0001232524-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252426000044/jazz-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:08:48.385317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}